About this journal
Aims and scope
Neuropsychiatric Disease and Treatment is an international, peer reviewed, open access journal publishing on all aspects of neuropsychiatric and neurological disorders. The journal is characterized by the rapid reporting of new and emerging clinical or pre-clinical studies, pharmacology and therapeutic strategies to overcome a wide range of conditions as well as the diagnosis, prognosis, epidemiology and genetic associations of these diseases.
Topics covered in this journal include:
- Biological basis and clinical treatment of Neuropsychiatric conditions such as Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorders, Anxiety and Depressive Disorders, Bipolar Disorders and Schizophrenia
- Biological basis and clinical treatment of Neurological conditions such as Dementia, Parkinson's Disease, Epilepsy, Multiple Sclerosis, Migraines, Strokes
- Research on the normal brain which gives insight into potential dysfunction, disease or the mechanisms of treatments
The journal welcomes submitted papers covering original research, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports.
Case reports/series submitted to Neuropsychiatric Disease and Treatment will be diverted to the Neuropsychiatric Disease and Treatment section of the International Medical Case Reports Journal. (Journal metric data for this journal can be accessed here).
When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors' own data through replication in an original sample.
All meta-analyses require a pre-submission check prior to submitting to Neuropsychiatric Disease and Treatment. Please complete the pre-submission check form here.
Journal metrics
Usage
- 679K annual downloads/views
Citation metrics
- 2.5 (2023) Impact Factor
- Q2 Impact Factor Best Quartile
- 3.0 (2023) 5 year IF
- 5.5 (2023) CiteScore (Scopus)
- Q2 CiteScore Best Quartile
- 0.975 (2023) SNIP
- 0.849 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor-in-Chief:
Dr Roger Pinder, Pharma, Independent Pharma Consultant, United Kingdom
Associate Editors-in-Chief:
Dr Jun Chen, Clinical Research Center, Shanghai Mental Health Center, China Mainland (PRC)
Dr Taro Kishi, Psychiatry, Fujita Health University School of Medicine, Japan
Dr Rakesh Kumar, Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA
Dr Yuping Ning, Department of Psychiatry, Mental Health Institute of the Second Xiangya Hospital, Central South University, China Mainland (PRC)
Editorial Board:
Hojjat Adeli is an Academy Professor at The Ohio State University. He is the recipient of eight Honorary Doctorates and elected into five European Academies. He is the co-author of 16 ground-breaking books including: Automated EEG-based Diagnosis of Neurological Disorders - Inventing the Future of Neurology (CRC Press 2010), USA
Dr Kristian Barlinn, Neurology, University Hospital Carl Gustav Carus Dresden, Germany
Professor Marlene Oscar Berman, Psychiatry, Neurology, Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts, USA, Dr. Berman also is a Research Scientist at the Department of Veterans Affairs Healthcare facility in Boston.
Prof. Dr. Francesca Bisulli, Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
Professor Tindara Capri, Department of Life and Health Sciences, Link Campus University, Rome, Italy
Professor Sau Man Sandra Chan, Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong
Prof. Dr. Lin Chen, Department of Neurosurgery, Tsinghua University Yuquan Hospital, China Mainland (PRC)
Professor Wai Tong Chien, The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
Dr Francesco Craig, Child and Adolescent Neuropsychiatry, Department of Cultures, Education and Society, University of Calabria, Italy, Italy
Alessandro Cuomo, MD-PhD, Assistant Professor in Psychiatry, Division of Psychiatry, Department of Molecular Medicine, University of Siena School of Medicine, Italy
Professor Anthony S David, Institute of Mental Health, University College London, United Kingdom
Professor Valsamma Eapen, Department and Faculty Head, School of Psychiatry, University of New South Wales, Australia
Professor Andrea Fagiolini, Molecular Medicine, University of Siena, Italy
Dr Mike Isaac, Psychiatry, South London & Maudsley NHS FT and University of London, United Kingdom
Prof. Dr. Andrey Iznak, Neurophysiology, Mental Health Research Centre, Russia
Professor Sidney Kennedy, Department of Psychiatry, University Health Network, University of Toronto, Canada
Dr Firas H Kobeissy, Department of Neuroscience, Morehouse School of Medicine, Atlanta, Georgia, USA
Professor Reinhard Michael Krausz, Psychiatry, The University of British Columbia, Canada
Dr John Markowitz, Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, United States
Professor Peter Martin, Psychiatry and Pharmacology, Vanderbilt Psychiatric Hospital, United States
Professor Julien Mendlewicz, Department of Psychiatry, Free University of Brussels, Belgium
Prof. Dr. Shinichi Mitsui, Department of Rehabilitation Sciences, Gunma University Graduate School of Health Sciences, Japan
Dr Zoran Pavlovic, Heruka Lifescience & Health Innovations, Serbia
Prof. Steven Potkin, Department of Psychiatry, University of California, Irvine, United States
Prof. Dr. Norman Sartorius, President, Association for the Improvement of Mental Health Programmes (AMH), Geneva, Switzerland
Prof. Dr. Alessandro Serretti, Department of Biomedical and NeuroMotor Sciences, Bologna University, Italy
Dr Timo Siepmann, Professor, PD Dr. med. habil, FAHA - Attending physician and director of the Telestroke Network Eastern Saxony (SOS TeleNET). He is also scientific director of the Master’s Program in Clinical Research at Dresden International University and Site Director of Dresden Site at Principles and Practice of Clinical Research, Harvard T.H. Chan School of Public Health. Professor Siepmann is an International Fellow of the American Heart Association, Germany
Dr Edoardo Spina, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy
Dr Eduard Vieta, Hospital Clinic, Institute of Neuroscience, University of Barcelona, Spain
Dr Ng Beng Yeong, Consultant Psychiatrist, Mount Elizabeth Medical Centre, Singapore
Professor Nathan Zasler, Virginia Commonwealth University and University of Virginia, Charlottesville, Virginia, United States
Abstracting and indexing
Neuropsychiatric Disease and Treatment is indexed/tracked/covered by the following services:
American Psychological Association's 'PsycINFO' database
Current Contents®/Clinical Medicine
Directory of Open Access Journals (DOAJ)
EMBASE (Elsevier)
ICAAP
Index Copernicus
Journal Citation Reports/Science Edition
Pubmed (NLM)
PubMed Central Selective Deposit Medicine & Health (NLM)
Science Citation Index Expanded (Clarivate Analytics)
Scopus (Elsevier)
Open access
Neuropsychiatric Disease and Treatment is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
News, offers and calls for papers
Continuous
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors